lionfish schreef op 17 oktober 2017 18:23:
het is maar een indicatie van wat ze met het geld gaan doen, maar het merendeel gaat blijkbaar naar ALX0171 gaan. Moet toch zijn dat ze daar heel sterk in geloven
The principal purposes of the global offering are to increase our financial flexibility to prepare for the commercialization of caplacizumab, if approved, advance our clinical pipeline, create a public market for our securities in the United States and facilitate our access to the U.S. public equity markets. We currently expect to use the net proceeds from this offering as follows:
• approximately $55.5 million to continue to build-out a sales, marketing and distribution infrastructure in preparation for the commercial launch of caplacizumab in Europe and the United States;
• approximately $101.6 million to advance the development of ALX-0171 through its Phase II trials; and
• approximately $2.0 million to advance the discovery and development of earlier stage products.
We expect to use the remainder of any net proceeds from the global offering for working capital and other general corporate purposes. We may also use a portion of the net proceeds to in-license, acquire or invest in complementary technologies, products or assets, either alone or together with a collaboration partner. However we have no current plan, commitments or obligations to do so.